Neuropsychiatry companies develop treatments, diagnostics and research technologies for conditions involving the interaction between brain function, behaviour and mental health. Their work spans psychiatric disorders, neurological symptoms and central nervous system drug discovery.
This category includes companies working on:
Browse 19 UK neuropsychiatry companies below.
Natural product-inspired small molecules for sexual and mental health
Kadence Bio is a clinical-stage biopharma company developing small molecule therapeutics for sexual and mental health. Its lead asset KH-001 is an on-demand oral treatment for premature ejaculation, developed from nature-inspired medicinal chemistry based on kanna plant alkaloids and optimised through standard drug…
Clinical-stage CNS drug discovery using human brain genomics
Cerevance is a clinical-stage biotechnology company developing small molecule therapeutics for neurodegenerative and psychiatric disorders. The company uses its proprietary platform to profile gene expression in specific neuronal and glial cell types from a collection of over 16,000 annotated human brain tissue…
Full-service CRO delivering UK clinical trials across dedicated research sites
MAC Clinical Research is a contract research organisation conducting Phase I to IV clinical trials for pharmaceutical and biotechnology sponsors. The company operates a fully owned network of dedicated research sites across the UK, including an MHRA accredited Phase I unit, backed by international offices. Services…
Real-world mental health and dementia data platform for drug development
Akrivia Health is a software company providing a real-world data and AI platform for neuroscience research and drug development. Its dataset of de-identified electronic health records from 6.3 million patients across 20 NHS Trusts covers mental health and dementia conditions, enriched through proprietary natural…
Biomarker-guided therapeutics for psychosis-related cognitive impairment
Monument Therapeutics is a clinical-stage biopharmaceutical company developing stratified treatments for neuropsychiatric conditions. Its lead programme, MT1988, is being evaluated in people at clinical high risk of psychosis. A randomised, placebo-controlled Phase 1/2 study dosed its first participant in March 2026…
Synthetic psilocybin therapy for treatment-resistant depression and PTSD
Compass Pathways is a clinical-stage biopharmaceutical company developing synthetic psilocybin-based treatments for mental health conditions. Its lead candidate, COMP360, is a proprietary synthesised psilocybin formulation administered alongside structured psychological support. COMP360 holds FDA Breakthrough Therapy…
Neuroactive therapeutics through genetic engineering of fungi and plants
Empyrean Neuroscience is a biopharma company that uses genetic engineering of fungi and plants to develop small molecule therapeutics for neuropsychiatric and neurologic disorders. Using CRISPR/Cas9 and proprietary transformation technologies, the platform enables precise modulation of neuroactive compound production.…
Systems biology platform for brain disease drug discovery and repurposing
BRAINCURES is a computational biotechnology company applying a systems biology approach to drug discovery for brain diseases, including Alzheimer's disease, depression, epilepsy, pain and schizophrenia. Its platform maps molecular relationships between compounds, genes and diseases, drawing on its own model of the…
Preclinical neuroscience CRO for translational drug development research
Transpharmation is a preclinical neuroscience contract research organisation providing translational pharmacology services to pharmaceutical and biotechnology companies. The company's therapeutic expertise spans EEG, cognition, epilepsy, pain, neurodegeneration and mood disorders including treatment-resistant…
Specialist CNS and psychiatric clinical trial design and delivery organisation
Clerkenwell Health is a London-based specialist contract research organisation providing clinical trial design, regulatory submission, and trial delivery services for CNS, psychiatric, and psychedelic-assisted therapy research. The company operates a purpose-built clinical site network, including an NHS-embedded…
AI-powered EEG platform for CNS clinical trials
Cumulus Neuroscience is a digital health software company providing an integrated brain monitoring and analytics platform for neuroscience clinical trials. Its platform combines a medical-grade EEG headset with machine learning analytics to generate objective, at-home physiological and cognitive biomarker data.…
Specialty pharmaceuticals for Parkinson's disease and related neurological conditions
Britannia Pharmaceuticals is a UK-based specialty pharmaceutical company developing and marketing treatments for Parkinson's disease and related conditions including psychosis. The company's product range includes apomorphine-based therapies available in multiple delivery formats, alongside clozapine-based treatment…
Digital cognitive assessment and CNS clinical trial software platform
Cambridge Cognition provides digital cognitive assessment and clinical trial technology for central nervous system drug development. Its validated computerised tests measure memory, attention and executive function across conditions including Alzheimer's disease and schizophrenia. The company also offers electronic…
Stem cell platform for precision psychiatry and drug discovery
MeOmics Precision Medicine is a biotechnology company developing a precision psychiatry platform that combines genomics, phenomics, and stem cell-based cellular assays to generate biomarkers for severe mental illness. Patient-derived neurons, stimulated via multi-electrode array recording, produce electrophysiological…
Small molecule neuromodulators for neuropsychiatric disorders
Draig Therapeutics is a clinical-stage biotech developing small molecule drugs that modulate the glutamate and GABA neurotransmitter pathways to treat neuropsychiatric disorders. Its lead candidate DT-101 is an AMPA receptor positive allosteric modulator in Phase 2 development for major depressive disorder. The…
Precision small molecule drugs for obsessive-compulsive disorder
Serenatis Bio is a preclinical-stage biotech developing small molecule drugs to treat obsessive-compulsive disorder (OCD). Its pipeline of three candidates targets distinct neurological mechanisms, including glutamate, AMPA, and dopamine pathways, with a biomarker-driven approach designed to match patients to…
Clinical-stage medicines for alcohol use disorder and PTSD
Solvonis Therapeutics is a clinical-stage biopharmaceutical company developing treatments for addiction and mental health disorders. Its lead programme is in Phase III for severe alcohol use disorder, with additional programmes addressing moderate to severe alcohol use disorder, post-traumatic stress disorder and…
Preclinical orexin-1 addiction therapies and CNS drug discovery
TheraCryf is an AIM-listed biotechnology company developing small-molecule therapies for addiction and other neuropsychiatric conditions. Its lead orexin-1 receptor antagonist programme is completing preclinical toxicology and regulatory preparations for a first-in-human Phase 1 trial in Australia. An Australian CRO…
AI-driven natural product discovery for neurological therapeutics
Pangea Bio is a clinical-stage biotechnology company developing small molecule therapeutics for neurological and neuropsychiatric disorders. Its proprietary AI platform screens natural and plant-derived chemical space, integrating ethnobotanical data with machine learning to identify novel CNS drug candidates with…